Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Patients With IBD Achieving Clinical Remission More Likely to Maintain Clinical Remission at 1 Year
May 8th 2023Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.
Read More
Meal-Related Gastrointestinal Symptoms Common in Patients With Disorders of Gut-Brain Interaction
May 8th 2023A proportion of patients reported triggering or worsening symptoms after a meal, with the largest proportion experiencing bloating or distention, followed by abdominal pain or discomfort, and epigastric pain.
Read More
Infliximab Biosimilar Not Associated With Adverse Events in IBD
May 7th 2023No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.
Read More
Anti-TNF Biosimilar Demonstrates Comparable Growth, Clinical Outcomes in Children With IBD
May 6th 2023Clinical outcomes of lab values were not statistically different in changes from baseline to 12 months between children with inflammatory bowel disease initiated on the TNF originator or biosimilar.
Read More
Biosimilars Month in Review: April 2023
May 2nd 2023The biosimilars month in review highlights the positive safety and efficacy data of 3 biosimilars used to treat rheumatic diseases, gastroenterologists discuss the risks and benefits of prescribing biosimilars to their patients, and physicians emphasize the importance of patient education.
Read More